reslizumab (Cinqair)


Original post, click here

Generic Name: reslizumab

Brand Name: Cinqair

Manufacturer: TEVA Canada Innovation

Indications: Asthma, eosinophilic

Manufacturer Requested Reimbursement Criteria1: Not applicable

Submission Type: Request For Advice

Project Status: Active

Biosimilar: No

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones1

Call for patient input posted October 24, 2018
Patient group input closed December 12, 2018
Patient input summary sent for review to patient input groups
Patient group comments on input summary closed
Request for Advice received October 24, 2018
Manufacturer informed of request for advice October 24, 2018
Manufacturer information or comments due November 07, 2018
Request for Advice initiated October 29, 2018
Draft CDR Request for Advice report sent to applicant
Comments from applicant on draft CDR Request for Advice report received
Redaction requests from applicant on draft CDR Request for Advice report received
CDR review team’s comments on draft CDR Request for Advice report sent to applicant
Canadian Drug Expert Committee (CDEC) meeting